ClinicalTrials.gg
RecruitingNCT06112704Updated Dec 2, 2024

HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors

A Phase 2 interventional study of HS-20093 in Advanced Solid Tumor, sponsored by Hansoh BioMedical R&D Company. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Hansoh BioMedical R&D Company (part of Hansoh Pharmaceutical Group Company Limited) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
220
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 502 studies in Esophageal Neoplasms with a site in China — 211 open to participants now, 238 under way, 28 of them phase 3. Esophageal Neoplasms · China.

Planned enrollment
103rd of 394
220 · median 80
Started
2024
with 56 others
Phase 2
146 of 502
72 open now
Primary completion
2026-07
later than 114 of 237 live
Registered
332nd of 502
by date

Among the 502 studies in Esophageal Neoplasms with a site in China, this one is the 103rd largest by planned enrollment of the 394 interventional ones that give a count, is one of 57 that started in 2024, is one of 146 in phase 2, reaches primary completion later than 114 of the 237 other live ones, and was the 332nd registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 503 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

211 of the 502 studies in Esophageal Neoplasms with a site in China are open now. Recruiting first, the newest first:

206 more — sign in →

All 211 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 502 studies in Esophageal Neoplasms with a site in China, or all of them as a file.
02

Study summary

HS-20093 is a humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. The objectives of this study are to investigate the anti-tumor activity, safety, pharmacokinetics and immunogenicity of HS-20093 in Chinese advanced esophageal carcinoma and other solid tumor patients.

Read the detailed description

This is an open-label, multi-center phase 2 study in Chinese adult participants with recurrent, locally advanced or metastatic esophageal carcinoma or other advanced solid tumors, which is designed to investigate the efficacy, safety, pharmacokinetics and immunogenicity of HS-20093. This study will consist of two parts: phase IIa and phase IIb.

Part 1 (phase IIa) will conducted in participants with relapsed, locally advanced or metastatic esophageal carcinoma and other advanced solid tumor. Subjects will receive one dose levels of HS-20093 intravenously every 3 weeks.

Part 2 (phase IIb) will enroll participants with relapsed, locally advanced or metastatic esophageal squamous cell carcinoma. One dose levels of HS-20093 will be administered as an intravenous (IV) infusion every 3 weeks.

03

Conditions studied

  • Advanced Solid Tumor

Keywords

  • Advanced solid tumor
  • Esophageal Carcinoma
  • B7-H3
  • antibody-drug conjugate (ADC)
  • HS-20093
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women aged more than or equal to (≥) 18 years.
  2. or cytologically confirmed, , locally advanced or esophageal carcinomas and other advanced solid tumor.
  3. At least one extra according to 1.1 (cavity structures such as oesophagus cannot serve as measurable lesions).
  4. Agree to provide fresh or and blood samples.
  5. (ECOG) Performance Status of 0\~1.
  6. Estimated >12 weeks.
  7. Agree to use medically accepted methods of .
  8. Men or women should be using adequate contraceptive measures throughout the study.
  9. Females subjects must not be pregnant at screening or have evidence of non-.
  10. Signed and dated Form.

Exclusion criteria

Exclusion Criteria:

Any of the following would exclude the subject from participation in the study:

  1. Treatment with any of the following:

    Previous or current treatment with B7-H3 targeted therapy Any cytotoxic chemotherapy, agents and anticancer drugs within 14 days prior to the first scheduled dose of HS-20093 Prior treatment with a monoclonal antibody within 28 days prior to the first scheduled dose of HS-20093 Local radiotherapy for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first scheduled dose of HS-20093 Major surgery within 4 weeks prior to the first scheduled dose of HS-20093

  2. Subjects with previous or concurrent
  3. Significant tumor invasion into adjacent organs (aorta or trachea) of esophageal lesions leading to higher risk of bleeding or fistula
  4. Inadequate bone marrow reserve or organ dysfunction.
  5. Evidence of cardiovascular risk
  6. Evidence of current severe or uncontrolled systemic diseases
  7. Evidence of mucosal or internal bleeding within 1 month prior to the first scheduled dose of HS-20093
  8. Severe infections occured within 4 weeks before the first dose
  9. The presence of active infectious diseases has been known before first dose such as , , ect
  10. History of neuropathy or mental disorders
  11. Pregnant or lactating female
  12. History of severe reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to HS-20093 or any of the components of HS-20093
  13. Known vaccination or hypersensitivity of any level within 4 weeks prior to the first scheduled dose of HS-20093
  14. Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator
  15. Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
220 participants (estimated)

Study arms

  • Experimental
    Phase IIa: Cohort 1

    Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.

    Drug: HS-20093

  • Experimental
    Phase IIa: Cohort 2

    Participants with advanced esophageal adenocarcinoma and gastroesophageal junction adenocarcinoma will be administered HS-20093.

    Drug: HS-20093

  • Experimental
    Phase IIa: Cohort 3

    Participants with other advanced solid tumor will be administered HS-20093.

    Drug: HS-20093

  • Experimental
    Phase IIb

    Participants with advanced esophageal squamous cell carcinoma will be administered HS-20093.

    Drug: HS-20093

Interventions

  • Intravenous (IV) infusion of HS-20093 Q3W; Participants will receive continuous treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR) determined by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.

    ORR was defined as the percentage of participants who achieved a best overall response (BOR) of confirmed Complete Response (CR) or Partial Response (PR), assessed by investigators based on RECIST version 1.1\[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)\].

    Time frame: From the first dose up to disease progression(PD)or withdrawal from study,whichever comes first,assessed up to 24 months.

Secondary outcomes

  1. DOR assessed by RECIST 1.1 criteria

    DOR was defined as the period from the first occurrence of CR or PR to PD or death from any cause. If no PD or death after CR/PR, the cut-off date of progression-free survival (PFS) would be used \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks)

    Time frame: From the first dose up to PD or death, whichever came first, assessed up to 24 months.

  2. Disease Control Rate (DCR) assessed by RECIST 1.1 criteria

    DCR was evaluated by the number of participants with best overall response of CR, PR and stable disease (SD) \[Confirmed CR/PR assessment require at least one repeat (≥4 weeks); SD shall be assessed at least 5 weeks after the first dose.

    Time frame: From the first dose up to PD or withdrawal from study, whichever came first, assessed up to 24 months.

  3. PFS assessed by RECIST 1.1 criteria

    PFS was defined as the time from first dose or random assignment (if any) to PD or death from any cause

    Time frame: From the first dose up to PD or death,whichever came first, assessed up to 24 months.

  4. Overall survival (OS)

    OS was defined as the time from the first dose or random assignment (if any) to death from any cause

    Time frame: From the first dose up to PD or death,whichever came first, assessed up to 24 months.

  5. Incidence and severity of adverse events

    AE assessed by investigator exclusively related to subject's underlying disease or medical condition \[graded according to the NCI Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0\]. Any untoward medical occurrence in a clinical study participant, whether or not considered related to the medicinal product. Incidence and severity of AEs are assessed according to vital signs, laboratory variables, physical examination, electrocardiogram, etc

    Time frame: From the first dose until 90 days after the last dose

  6. Characterize the pharmacokinetic parameters of HS-20093

    Characterize the pharmacokinetic parameters of HS-20093

    Time frame: Cycle 1 Day 1 up to 90 days after the last dose

  7. Assess the incidence of anti-drug antibodies (ADAs)

    Serum samples were collected for the determination of anti-drug antibody (ADA) at designated time points

    Time frame: Cycle 1 Day 1 up to 90 days after the last dose

07

Study locations

17 of 21 sites recruiting
  • Anhui Provincial Cancer Hospital
    Hefei, Anhui 230031, China
    Recruiting
  • Fujian Provincial Tumor Hospital
    Fujian, Fujian 350014, China
    Not yet recruiting
  • The 900th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army
    Fuzhou, Fujian 350014, China
    Recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong 510000, China
    Recruiting
  • Harbin Medical University Cancer Hospital
    Harbin, Heilongjiang 1540000, China
    Recruiting
  • Tumour Hospital of Anyang city
    Anyang, Henan 455000, China
    Recruiting
  • The First Affiliated Hospital of Henan University of Science & Technology
    Luoyang, Henan 471003, China
    Recruiting
  • Nanyang Central Hospital
    Nanyang, Henan 422000, China
    Recruiting
  • The First Affiliated Hospital of Xinxiang Medical University
    Xinxiang, Henan 453100, China
    Recruiting
  • Henan Cancer Hospital
    Zhengzhou, Henan 450003, China
    Recruiting
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
  • Tongji Hospital, affiliated with Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
    Recruiting
  • Hubei Cancer Hospital
    Wuhan, Hubei 430079, China
    Not yet recruiting
  • Nantong Tumor Hospital
    Nantong, Jiangsu 226300, China
    Recruiting
  • Jiangyin People's Hospital
    Wuxi, Jiangsu 214400, China
    Recruiting
  • Jiangxi Provincial Tumor Hospital
    Nanchang, Jiangxi 330038, China
    Not yet recruiting
  • Liaoning Cancer Hospital
    Shenyang, Liaoning 110000, China
    Recruiting
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110002, China
    Recruiting
  • Affiliated Hospital of Jining Medical University
    Jining, Shandong 272000, China
    Not yet recruiting
  • Sichuan Cancer Hospital&Institude, Sichuan Cancer Center,Affiliate Cancer Hospital Of University Of Electronic Science and Technology of China
    Chengdu, Sichuan 610041, China
    Recruiting
  • The Affiliated Cancer Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830011, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Jul 2026, 29 months after the start.

Of 198 phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 78. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2023
First posted
Nov 1, 2023
StartActual
Feb 6, 2024
Primary completionEst.
Jul 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06112704
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Feb 6, 2024
Primary completion
Jul 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Dec 2, 2024

Study contacts

Yun Sun
Contact
suny20@hspharm.com
18321785381

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risvutatug rezetecan

Start the discussion